Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in Chinese patients (pts) with resectable NSCLC in CheckMate 816
| Title | Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in Chinese patients (pts) with resectable NSCLC in CheckMate 816 |
|---|---|
| Description | This abstract will be open to public at AACR 2023 Annual Meeting. |
| Organism | Homo sapiens |
| Data Type | Biomarker Data |
| Data Accessibility | Controlled-access |
| BioProject | PRJCA012345 |
| Release Date | 2023-04-14 |
| Submitter | Changli Wang (wangchangli309@163.com) |
| Organization | Tianjin Cancer Hospital |
| Submission Date | 2023-02-08 |
HTTP download speed may be slow. It is highly recommended that you download the dataset using a dedicated FTP tool (such as FileZilla Client).
| File ID | File Title | Number/Samples | File Type | File Size | File Suffix | Download Times | Download |
|---|---|---|---|---|---|---|---|
| OMIX002943-02 | Results__AACR 2023 Annual Meeting | 1 | Biomarker Data | 13.5 KB | rar | 0 | Controlled |